InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.017 0.003 (21.43%)+
Announcement
Release
23 Feb 2026 9:45AM
Price at Release
$0.014
Full Release
download
Summary
Neurotech International Limited announced positive results from a 90-day GLP toxicology study of their lead drug candidate NTI164, conducted in non-rodent species (Beagle dogs). The study confirmed NTI164's favourable safety and tolerability profile across all dose levels, with no mortality or dose-limiting toxicities observed. This includes doses up to 216 mg/kg/day, representing approximately ten times the highest prescribed human dose. Additional central nervous system-focused safety assessments, guided by the FDA, identified no safety concerns, supporting the drug's continued development as a potential chronic therapy for neurological disorders. These findings enhance the company's safety package for future regulatory interactions.
Key Points
  • NTI164 demonstrated a favourable safety profile in a 90-day GLP toxicology study.
  • The study was conducted in non-rodent species, specifically Beagle dogs.
  • NTI164 was well tolerated at doses up to 216 mg/kg/day, which is approximately ten times the highest prescribed human dose.
  • No mortality or dose-limiting toxicities were observed during the study.
  • The study included additional assessments focused on the central nervous system, guided by the FDA.
  • Mild and reversible treatment-related findings were observed, with full recovery after a 14-day non-dosing period.
  • The results support the continued clinical development of NTI164 as a potential chronic therapy for neurological disorders.
  • The study strengthens the safety package required for future regulatory interactions and clinical development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.